ALUMIS INC (ALMS) Stock Overview
USA - NASDAQ:ALMS - US0223071020 - Common Stock
ALMS Key Statistics, Chart & Performance
The current stock price of ALMS is 4.16 USD. In the past month the price decreased by -14.23%. In the past year, price decreased by -63.73%.
ALMS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 47.35 | 723.77B | ||
| JNJ | JOHNSON & JOHNSON | 17.65 | 424.98B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 14.48 | 254.16B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 17.47 | 240.47B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.87 | 237.68B | ||
| MRK | MERCK & CO. INC. | 10.53 | 202.54B | ||
| PFE | PFIZER INC | 7.05 | 135.88B | ||
| SNY | SANOFI-ADR | 10.46 | 114.29B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.89 | 94.32B | ||
| GSK | GSK PLC-SPON ADR | 8.76 | 80.68B | ||
| ZTS | ZOETIS INC | 23.71 | 65.35B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 52.14 | 47.75B |
Related stock screener links
About ALMS
Company Profile
Alumis, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The company is headquartered in South San Francisco, California and currently employs 250 full-time employees. The company went IPO on 2024-06-28. The firm is engaged in developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, the Company is developing a pipeline of oral tyrosine kinase 2 (TYK2) inhibitors, consisting of ESK-001 for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 for the treatment of neuroinflammatory and neurodegenerative diseases such as multiple sclerosis and Parkinson’s Disease. In addition, its pipeline also includes lonigutamab, a subcutaneously delivered anti-insulin-like growth factor 1 receptor therapy for the treatment of thyroid eye disease, as well as several preclinical programs identified through this precision approach.
Company Info
ALUMIS INC
280 East Grand Avenue
South San Francisco CALIFORNIA US
Employees: 250
Phone: 16502316625
ALUMIS INC / ALMS FAQ
What is the stock price of ALUMIS INC today?
The current stock price of ALMS is 4.16 USD. The price decreased by -5.02% in the last trading session.
What is the ticker symbol for ALUMIS INC stock?
The exchange symbol of ALUMIS INC is ALMS and it is listed on the Nasdaq exchange.
On which exchange is ALMS stock listed?
ALMS stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ALUMIS INC stock?
14 analysts have analysed ALMS and the average price target is 19.38 USD. This implies a price increase of 365.87% is expected in the next year compared to the current price of 4.16. Check the ALUMIS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ALUMIS INC worth?
ALUMIS INC (ALMS) has a market capitalization of 432.89M USD. This makes ALMS a Small Cap stock.
How many employees does ALUMIS INC have?
ALUMIS INC (ALMS) currently has 250 employees.
What are the support and resistance levels for ALUMIS INC (ALMS) stock?
ALUMIS INC (ALMS) has a resistance level at 4.39. Check the full technical report for a detailed analysis of ALMS support and resistance levels.
Should I buy ALUMIS INC (ALMS) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ALMS, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ALMS, evaluating the profitability, health, valuation and growth aspects
- ALUMIS INC (ALMS) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ALUMIS INC (ALMS) Sales and EPS estimates to see what analysts future expectations are.
- ALUMIS INC (ALMS) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ALUMIS INC (ALMS) Insider and Institutional Ownership to learn about the owners and their transactions.
- ALUMIS INC (ALMS) Stock Chart to make your own analysis
- ALUMIS INC (ALMS) Latest news and press-releases to stay up to date.
Does ALUMIS INC (ALMS) stock pay dividends?
ALMS does not pay a dividend.
When does ALUMIS INC (ALMS) report earnings?
ALUMIS INC (ALMS) will report earnings on 2025-11-11.
What is the Price/Earnings (PE) ratio of ALUMIS INC (ALMS)?
ALUMIS INC (ALMS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-5.46).
What is the Short Interest ratio of ALUMIS INC (ALMS) stock?
The outstanding short interest for ALUMIS INC (ALMS) is 3.23% of its float. Check the ownership tab for more information on the ALMS short interest.
ALMS Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to ALMS. When comparing the yearly performance of all stocks, ALMS is a bad performer in the overall market: 83.09% of all stocks are doing better.
ALMS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ALMS. ALMS has a great financial health rating, but its profitability evaluates not so good.
ALMS Financial Highlights
Over the last trailing twelve months ALMS reported a non-GAAP Earnings per Share(EPS) of -5.46. The EPS decreased by -80.89% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -37.24% | ||
| ROE | -46.88% | ||
| Debt/Equity | 0 |
ALMS Forecast & Estimates
14 analysts have analysed ALMS and the average price target is 19.38 USD. This implies a price increase of 365.87% is expected in the next year compared to the current price of 4.16.